Skip to Content
Merck
  • The effect of hyperglycemia on the pharmacokinetics of valproic acid studied by high-performance liquid chromatography with electrochemical detection.

The effect of hyperglycemia on the pharmacokinetics of valproic acid studied by high-performance liquid chromatography with electrochemical detection.

Journal of pharmaceutical and biomedical analysis (2014-05-13)
Akira Kotani, Tomoko Kotani, Nana Ishii, Hideki Hakamata, Fumiyo Kusu
ABSTRACT

The effects of hyperglycemia on the pharmacokinetics of valproic acid (VPA) were examined by time-concentration profiles of plasma VPA accompanied with blood glucose (BG) changing. In addition, time-concentration profiles of plasma free fatty acids (FFAs) were also obtained to examine the interaction between VPA and FFAs in vivo. For the experiments in vivo, normal rats, given multiple doses of maltose orally, and diabetic rats, which were made to maintain hyperglycemia, were used. Plasma VPA and FFA were determined by high-performance liquid chromatography with electrochemical detection (HPLC-ECD) systems based on the reduction of quinone for the selective determination of acids, respectively. BG was determined by pocket-size glucose meter. The maximum plasma concentrations (Cmax) of VPA in normal rats given multiple doses of maltose orally and in diabetic rats were remarkably decreased in comparison with those in the control rats. From the present study, it was shown that the metabolism of plasma VPA is accelerated under hyperglycemia. Moreover, we also found that VPA was preferentially metabolized in comparison with the plasma FFA in vivo.

MATERIALS
Product Number
Brand
Product Description

Valproic acid for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Valproic acid, United States Pharmacopeia (USP) Reference Standard
Valproic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
2-Propylpentanoic acid
USP
Dehydrated Alcohol, United States Pharmacopeia (USP) Reference Standard
USP
Palmitic acid, United States Pharmacopeia (USP) Reference Standard
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Palmitic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sodium valproate, European Pharmacopoeia (EP) Reference Standard
Supelco
Nonanoic acid, analytical standard
Supelco
Palmitic acid, analytical standard
Sigma-Aldrich
Palmitic acid, ≥98% palmitic acid basis (GC)
Sigma-Aldrich
Linoleic acid, technical, 58-74% (GC)
Supelco
Linoleic acid, analytical standard
Supelco
Ethanol solution, certified reference material, 2000 μg/mL in methanol
Sigma-Aldrich
Palmitic acid, ≥98%, FCC, FG
Sigma-Aldrich
Nonanoic acid, 96%
Supelco
Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Nonanoic acid, ≥96%, FG
Sigma-Aldrich
Palmitic acid, ≥99%
Sigma-Aldrich
Linoleic acid, liquid, BioReagent, suitable for cell culture
Sigma-Aldrich
Linoleic acid, ≥99%
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Sigma-Aldrich
Nonanoic acid, ≥97%
Sigma-Aldrich
Ethanol, tested according to Ph. Eur.
Supelco
Dehydrated Alcohol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Palmitic acid, natural, 98%, FG